ArticleStructure (London, England : 1993)2014
Structural insights into the inhibition of Wnt signaling by cancer antigen 5T4/Wnt-activated inhibitory factor 1.
Article in Structure (London, England : 1993), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 53 citations in OpenAlex.
- Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers.Cell reports. Medicine · 2025Trial
- In situ structure of the human gap junction.Science advances · 2026Article
- Proteomic Signatures in Extracellular Vesicles as Predictive Markers of Neural and Cardiac Differentiation from Human iPSCs.Mass spectrometry (Tokyo, Japan) · 2026Article
- Preclinical Characterization of XB010: A Novel Antibody-Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4.Molecular cancer therapeutics · 2025Article
- Uncovering the glutamate carboxypeptidase II microenvironment using a multi-labeling proteomic approach.Scientific reports · 2025Article
- Wnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease.Bone research · 2024Review
- A specific olfactory bulb interneuron subtype Tpbg/5T4 generated at embryonic and neonatal stages.Frontiers in neural circuits · 2024Review
- Quantitative Proteomics for the Development and Manufacturing of Human-Induced Pluripotent Stem Cell-Derived Neural Stem Cells Using Data-Independent Acquisition Mass Spectrometry.Journal of proteome research · 2023Article
- Parkinson's Disease Gene Biomarkers Screened by the LASSO and SVM Algorithms.Brain sciences · 2023Article
- Trophoblast glycoprotein is required for efficient synaptic vesicle exocytosis from retinal rod bipolar cells.Frontiers in cellular neuroscience · 2023Article
- Dynamics of the secreted frizzled related protein Sizzled and potential implications for binding to bone morphogenetic protein-1 (BMP-1).Scientific reports · 2022Article
- A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Trophoblast glycoprotein is a new candidate gene for Parkinson's disease.NPJ Parkinson's disease · 2021Article
- Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein.eLife · 2020Article
- Expression and distribution of trophoblast glycoprotein in the mouse retina.The Journal of comparative neurology · 2020Article
- LRR-Containing Oncofetal Trophoblast Glycoprotein 5T4 Shapes Neural Circuits in Olfactory and Visual Systems.Frontiers in molecular neuroscience · 2020Review
- Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope.The Journal of biological chemistry · 2019Article
- Identification of PKCα-dependent phosphoproteins in mouse retina.Journal of proteomics · 2019Article
- Cancer stem cell mobilization and therapeutic targeting of the 5T4 oncofetal antigen.Therapeutic advances in vaccines and immunotherapy · 2019Review
- Expression of Oncofetal Antigen 5T4 in Murine Taste Papillae.Frontiers in cellular neuroscience · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The tumor antigen 5T4/WAIF1 (Wnt-activated inhibitory factor 1; also known as Trophoblast glycoprotein TPBG) is a cell surface protein targeted in multiple cancer immunotherapy clinical trials. Recently, it has been shown that 5T4/WAIF1 inhibits Wnt/β-catenin signaling, a signaling system central to many developmental and pathological processes. Wnt/β-catenin signaling is controlled by multiple inhibitors and activators. Here, we report crystal structures for the extracellular domain of 5T4/WAIF1 at 1.8 Å resolution. They reveal a highly glycosylated, rigid core, comprising eight leucine-rich repeats (LRRs), which serves as a platform to present evolutionarily conserved surface residues in the N-terminal LRR1. Structural and cell-based analyses, coupled with previously reported in vivo data, suggest that Tyr325 plus the LRR1 surface centered on a second exposed aromatic residue, Phe97, are essential for inhibition of Wnt/β-catenin signaling. These results provide a structural basis for the development of 5T4/WAIF1-targeted therapies that preserve or block 5T4/WAIF1-mediated inhibition of Wnt/β-catenin signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.